Biosergen AB (FRA:8N10) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8N10 Biosergen AB FRA:8N10
18 GF Score
Price €0.51
View Full Analysis

What is Biosergen AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:8N10
18GF Score
Biosergen AB FRA:8N10
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosergen AB Business Description

Other Exchanges BIOSGN:Sweden
Address Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
18GF Score

Get the complete analysis for FRA:8N10

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.51
Price